Entrar/Registro  
INICIO ENGLISH
 
Gaceta Médica de México
   
MENÚ

Contenido por año, Vol. y Num.

Índice de este artículo

Información General

Instrucciones para Autores

Mensajes al Editor

Directorio






>Revistas >Gaceta Médica de México >Año 2015, No. 1


Zamorano-Jiménez CA, Baptista-González HA, Bouchán-Valencia P, Granados-Cepeda ML, Trueba-Gómez R, Coeto-Barona G, Rosenfeld-Mann F, Rosa-Mireles LB, Meléndez-Ramírez R
Identificación molecular de la glucosa-6-fosfato deshidrogenasa (G6PD) detectada en el tamiz neonatal
Gac Med Mex 2015; 151 (1)

Idioma: Español
Referencias bibliográficas: 24
Paginas: 34-41
Archivo PDF: 85.09 Kb.


Texto completo




RESUMEN

Objetivo: Presentar la estrategia de identificación de las variantes moleculares de la G6PD detectados en el tamiz neonatal (TN). Material y métodos: Serie de casos incidentes de recién nacidos (RN) detectados en el TN con deficiencia de G6PD. A partir de DNA nuclear, con la metodología de reacción en cadena de la polimerasa en tiempo real (PCR-TR) se buscaron las variantes moleculares de la G6PD: G202A, A376G, T968C y C563T. Resultados: Se evaluaron 21,619 neonatos, 41 casos fueron reactivos en el TN para G6PD (tasa de 189.6/100,000 RN tamizados); en 34 casos se confirmó la variante molecular de G6PD (tasa de 157.3/100,000 RN tamizados). La combinación alélica más frecuente fue G202A/A376G (proporción y actividad promedio de G6PD de 0.460 y 1.72 ± 0.35 U/g de hemoglobina [Hb], respectivamente), seguida de G202A (0.170 y 1.74 ± 0.27 U/g de Hb) y de la combinación A376G/T968C (proporción 0.150 y 1.10 ± 0.44 U/g de Hb). La variante alélica T968C mostró actividad enzimática más baja que el resto (1.1 ± 0.4; p = 0.02). Se detectaron dos mujeres con deficiencia de G6PD, con variante G202A/A376G y G202A. Conclusiones: Esta estrategia molecular permite identificar las variantes involucradas hasta en el 80% de los casos. Los alelos de origen africano fueron prevalentes.


Palabras clave: Deficiencia de la glucosa-6-fosfato deshidrogenasa, Enfermedad hemolítica del recién nacido, Ictericia neonatal, Anemia neonatal, Tamiz neonatal.


REFERENCIAS

  1. Andermann A, Blancquaert I, Beauchamp S, Dery V. Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years. Bull World Health Organ. 2008;86(4):317-9.

  2. American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system-- executive summary. Pediatrics. 2006;117(5 Pt 2):S296-307.

  3. Wang FL, Boo NY, Ainoon O, Wong MK. Comparison of detection of glucose-6-phosphate dehydrogenase deficiency using fluorescent spot test, enzyme assay and molecular method for prediction of severe neonatal hyperbilirubinaemia. Singapore Med J. 2009;50(1):62-7.

  4. Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3): 267-78.

  5. Beutler E. Glucose-6-phosphate dehydrogenase deficiency: a historical perspective. Blood. 2008;111(1):16-24.

  6. Medina MD, Vaca G, López-Guido B, Westwood B, Beutler E. Molecular genetics of glucose-6-phosphate dehydrogenase deficiency in Mexico. Blood Cells Mol Dis. 1997;23(1):88-94.

  7. Lisker R, Loria A, Cordova MS. Studies on Several Genetic Hematological Traits of the Mexican Population. 8. Hemoglobin S, Glucose-6-Phosphate Dehydrogenase Deficiency, and Other Characteristics in a Malarial Region. Am J Hum Genet. 1965;17:179-87.

  8. Nock ML, Johnson EM, Krugman RR, et al. Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. J Perinatol. 2011;31(2):112-7.

  9. Vaca G, Ibarra B, Hernández A, et al. Screening for inborn errors of the erythrocyte metabolism in Northwestern Mexico. Acta Anthropogenet. 1982;6(4):255-64.

  10. González-Quiroga G, Ramírez-Del Río JL, Cerda-Flores RM, Garza-Chapa R. Frequency and origin of G-6-PD deficiency among icteric newborns in the metropolitan area of Monterrey, Nuevo Leon, Mexico. Gene Geogr. 1994;8(3):157-64.

  11. Little J, Higgins JP, Ioannidis JP, et al. STrengthening the REporting of Genetic Association studies (STREGA)--an extension of the STROBE statement. Eur J Clin Invest. 2009;39(4):247-66.

  12. WHO-Working-Group. Glucose-6-phosphate dehydrogenase deficiency. WHO Working Group. Bull World Health Organ. 1989;67(6):601-11.

  13. Vaca G, Arambula E, Esparza A. Molecular heterogeneity of glucose- 6-phosphate dehydrogenase deficiency in Mexico: overall results of a 7-year project. Blood Cells Mol Dis. 2002;28(3):436-44.

  14. Cobian JG, Sánchez-López JY, Magana MT, Chavez ML, Perea FJ, Ibarra B. Types and frequencies of hemoglobin disorders in the pacific coast of four states of Mexico. Rev Invest Clin. 2009;61(5):399-404.

  15. Zhang DT, Hu LH, Yang YZ. Detection of three common G6PD gene mutations in Chinese individuals by probe melting curves. Clin Biochem. 2005;38(4):390-4.

  16. Beutler E, Kuhl W, Ramírez E, Lisker R. Some Mexican glucose-6-phosphate dehydrogenase variants revisited. Hum Genet. 1991;86(4):371-4.

  17. Vaca G, Arambula E, Monsalvo A, et al. Glucose-6-phosphate dehydrogenase (G-6-PD) mutations in Mexico: four new G-6-PD variants. Blood Cells Mol Dis. 2003;31(1):112-20.

  18. Arambula E, Aguilar LJ, Vaca G. Glucose-6-phosphate dehydrogenase mutations and haplotypes in Mexican Mestizos. Blood Cells Mol Dis. 2000;26(4):387-94.

  19. Lin Z, Fontaine JM, Freer DE, Naylor EW. Alternative DNA-based newborn screening for glucose-6-phosphate dehydrogenase deficiency. Mol Genet Metab. 2005;86(1-2):212-9.

  20. Simopoulos AP. Genetic screening: programs, principles, and research-- thirty years later. Reviewing the recommendations of the Committee for the Study of Inborn Errors of Metabolism (SIEM). Public Health Genomics. 2009;12(2):105-11.

  21. Kaye CI, Accurso F, La Franchi S, et al. Newborn screening fact sheets. Pediatrics. 2006;118(3):e934-63.

  22. Watchko JF. Identification of neonates at risk for hazardous hyperbilirubinemia: emerging clinical insights. Pediatr Clin North Am. 2009;56(3):671-87.

  23. Kaplan M, Hammerman C. Glucose-6-phosphate dehydrogenase deficiency and severe neonatal hyperbilirubinemia: a complexity of interactions between genes and environment. Semin Fetal Neonatal Med. 2010;15(3):148-56.

  24. Nock ML, Johnson EM, Krugman RR, et al. Implementation and analysis of a pilot in-hospital newborn screening program for glucose-6-phosphate dehydrogenase deficiency in the United States. J Perinatol. 2011;31(2):112-7.



>Revistas >Gaceta Médica de México >Año2015, No. 1
 

· Indice de Publicaciones 
· ligas de Interes 






       
Derechos Resevados 2019